U.S. FDA Confirms Daiichi/Lilly Prasugrel Advisory Committee Review; What Will Panel Membership Entail?

As preparations get underway for the Feb. 3 advisory committee review of Lilly and Daiichi Sankyo's platelet inhibitor prasugrel, one indicator of the drug's prospects will be the individuals who are asked by U.S. FDA to serve on the expert panel